Relapses Linked to Accelerated Disability Progression in SPMS
For patients with secondary progressive multiple sclerosis, relapses are associated with accelerated disability progression.
Relapsing Remitting Multiple Sclerosis
Greater Proportion of RMS Patients Achieve NEDA-3 With Ofatumumab vs Teriflunomide
Treatment with ofatumumab was associated with a greater proportion of patients with relapsing forms of multiple sclerosis achieving no evidence of disease activity, compared with those who received teriflunomide.
Monomethyl Fumarate Gets Final FDA Approval for Multiple Sclerosis
The FDA has granted final approval to Bafiertam™ (monomethyl fumarate; Banner Life Sciences) for the treatment of relapsing forms of multiple sclerosis.
Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis
The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
Ofatumumab Under Review for Relapsing Forms of Multiple Sclerosis
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ofatumumab (Novartis) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
First Generic Versions of Fingolimod Gain FDA Approval
The FDA has approved the first generic versions of fingolimod for the treatment of relapsing forms of multiple sclerosis in adults.
Cortical Atrophy and Cognitive Decline Accelerated in Stable and Progressive Multiple Sclerosis
Cortical atrophy and cognitive decline accelerate together during the course of multiple sclerosis.
Diroximel Fumarate Approved for Relapsing Forms of Multiple Sclerosis
Vumerity (diroximel fumarate; Biogen) has been approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Patients With Multiple Sclerosis Experience a Wearing-Off Effect During Natalizumab Treatment
More than half of patients with multiple sclerosis experienced a wearing-off effect during treatment with natalizumab.
Therapeutic Potential for Subcutaneous Ofatumumab in Relapsing Multiple Sclerosis
The results of the identically designed ASCLEPIOS I and II phase 3 trials evaluating the effect of ofatumumab versus teriflunomide in participants with relapsing multiple sclerosis were presented at ECTRIMS 2019.
-
Loading...
-
Loading...
Next post in ECTRIMS 2019
